source
- Pathos AI acquires bispecific ADC from Alphamab and secures AstraZeneca partnershipPathos AI announced it will pay $125 million upfront for the rights to JSKN016, a bispecific TROP2/HER3 antibody‑drug conjugate from China’s Alphamab Oncology. The agreement also includes up to $2.…
- Amgen halts development of early-stage obesity drug AMG 513, shifting focus to phase-3 candidate MariTideAmgen announced it is stopping work on AMG 513, an early-stage obesity therapy, during its second-quarter earnings call. The decision follows a previous FDA clinical hold in early 2025 that was la…